STAT3 hyperactivation in tumor cells can occur as a result of increased IL-6 levels in the serum and/or the tumor microenvironment, or as a result of loss-of-function mutations affecting STAT3 negative regulators. This evidence concerns the gene IL6 and neoplasm.